China NMPA Product Recall - Subcutaneous implantable cardioverter defibrillator

The National Medical Products Administration (NMPA) has publicized a significant Class I voluntary recall initiated by Boston Scientific Corporation, specifically through its regional entity, Boston Scientific International Medical Trade (Shanghai) Co., Ltd. This action, reported and published on March 3, 2021, addresses critical safety concerns with certain models and batches of the company's subcutaneous implantable cardioverter defibrillators. The central issue identified is a potential voltage overload that can occur during the device's discharge therapy. This defect is particularly serious given that implantable cardioverter defibrillators are life-sustaining devices designed to correct life-threatening heart rhythm disturbances. The voltage overload could potentially lead to serious adverse events for patients relying on these implants. The NMPA's announcement highlights its role in regulatory oversight, ensuring the safety and efficacy of medical products circulating within China. Boston Scientific Corporation is proactively recalling these products to mitigate patient risk, emphasizing the severity indicated by the Class I designation, which signifies a high probability of serious health consequences or death. Comprehensive details regarding the affected products are available within the accompanying "Medical Device Recall Event Report Form."